Drugs / Quadrivalent Meningococcal Polysaccharide (A, C, Y, and W-135) Tetanus Protein Conjugate
Quadrivalent Meningococcal Polysaccharide (A, C, Y, and W-135) Tetanus Protein Conjugate
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01049035 | Dec 2009 → Feb 2012 | meningitis, meningococcal infection | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Quadrivalent Meningococcal Polysaccharide (A, C, Y, and W-135) Tetanus Protein Conjugate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01049035 ↗ |
| Known as | MenACYW Conjugate vaccine | “The purpose of this study was to evaluate the optimal vaccination schedule for a Quadrivalent Meningococcal Polysaccharide (A, C, Y and W-135) Tetanus Protein Conjugate Vaccine...” NCT01049035 ↗ |
| Known as | MenACYW-TT | “The MenACYW-TT conjugate vaccine is approved for prevention of invasive meningococcal disease (IMD) as a single dose in individuals ≥2 years of age in the United States and ≥12...” PMID 35144847 ↗ Feb 2022 |
| Modality | Vaccine | “MenACYW-TT conjugate vaccine” PMID 35144847 ↗ Feb 2022 |
| Route | Intramuscular | “0.5 milliliter (mL), Intramuscular (IM) injection” NCT01049035 ↗ |